Pulling SEC filings + quote and writing the call…

Passage BIO, Inc.
Next earnings Aug 10, 2026 · consensus $-2.85 EPS
Mixed signals in the latest filings.
Passage BIO, Inc. shows limited reported revenue, and -242.7% ROE.
Sources: SEC EDGAR (CIK 0001787297, latest 10-Q filed 2026-05-12) · EODHD · as of 6/23/2026, 12:10:41 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$186M | -$138M | -$108M | -$70.4M | -$49.3M |
| Net income | -$185M | -$136M | -$102M | -$64.8M | -$45.5M |
| Diluted EPS | -$3.48 | -$2.50 | -$1.86 | -$21.04 | -$14.35 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1047 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.